A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Imugene Limited
Seagen Inc.
Jazz Pharmaceuticals
Seagen Inc.
Tango Therapeutics, Inc.
TriSalus Life Sciences, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Toray Industries, Inc
Medivir
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Xencor, Inc.
SMT bio Co., Ltd.